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Abstract
Background
Because acute liver failure (ALF) patients share many clinical features with severe sepsis
and septic shock, identifying bacterial infection clinically in ALF patients is challenging. Pro-
calcitonin (PCT) has proven to be a useful marker in detecting bacterial infection. We sought
to determine whether PCT discriminated between presence and absence of infection in
patients with ALF.
Method
Retrospective analysis of data and samples of 115 ALF patients from the United States
Acute Liver Failure Study Group randomly selected from 1863 patients were classified for
disease severity and ALF etiology. Twenty uninfected chronic liver disease (CLD) subjects
served as controls.
Results
Procalcitonin concentrations in most samples were elevated, with median values for all ALF
groups near or above a 2.0 ng/mL cut-off that generally indicates severe sepsis. While PCT
concentrations increased somewhat with apparent liver injury severity, there were no differ-
ences in PCT levels between the pre-defined severity groups–non-SIRS and SIRS groups
with no documented infections and Severe Sepsis and Septic Shock groups with docu-
mented infections, (p = 0.169). PCT values from CLD patients differed from all ALF groups
(median CLD PCT value 0.104 ng/mL, (p0.001)). Subjects with acetaminophen (APAP)
toxicity, many without evidence of infection, demonstrated median PCT >2.0 ng/mL, regard-
less of SIRS features, while some culture positive subjects had PCT values <2.0 ng/mL.
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Summary/Conclusions
While PCT appears to be a robust assay for detecting bacterial infection in the general pop-
ulation, there was poor discrimination between ALF patients with or without bacterial infec-
tion presumably because of the massive inflammation observed. Severe hepatocyte
necrosis with inflammation results in elevated PCT levels, rendering this biomarker unreli-
able in the ALF setting.
Introduction
Patients with acute liver failure (ALF) have an increased risk of infection approaching 80%
thus predisposing to sepsis-related multi-organ failure [1–3]. Infections have been shown to
worsen hepatic encephalopathy (HE) and are one of the most common causes of multi-organ
dysfunction and death in ALF [3, 4].
Signs and symptoms of ALF closely mimic those of sepsis making it difficult to accurately
identify infection in this setting. The diagnosis of infection or sepsis (usually based upon a posi-
tive culture) is often delayed or not detected, even when presumptive evidence is very strong.
Identification of a bacterial infection by culture requires 48–72 hours to complete and the effi-
cacy of prophylactic antibiotics to contain an established infection remains difficult to prove. A
more rapid method to identify infection is a worthwhile goal.
Procalcitonin (PCT) is a biomarker for detection of bacterial infection that has shown early
promise. PCT consists of 116 amino acids and has a MW of 14.5 kDa. A precursor of calcito-
nin, the primary source of PCT is the parafollicular C cells of the thyroid gland. Calcitonin has
a hypocalcemic and hypophosphatemic effect that inhibits bone resorption and stimulates
excretion of phosphorus, calcium, and sodium by the kidney and is used as a biomarker of
medullary thyroid cancer but its relation to systemic inflammation remains unclear [5–8].
In studies of patients with sepsis, pneumonia, and other types of infections, PCT has been
shown to be a reliable and rapidly available indicator of bacterial infection, useful in guiding
antimicrobial therapy. PCT has been examined in patients who have had a liver transplant and
in patients hospitalized with chronic liver disease (cirrhosis; CLD), but there are few studies of
patients with ALF. [9–14].
In this study, we sought to determine whether PCT would aid in the identification of infec-
tion in ALF patients, since distinguishing sepsis from ALF without infection has prognostic
and therapeutic implications. We utilized the extensive registry and serum bank of the U. S.
Acute Liver Failure Study Group (USALFSG) as well as 2 local repositories for CLD control
sera, to address this question.
Materials and Methods
Study Population
This study included patients prospectively enrolled in the US Acute Liver Failure Study (estab-
lished in January 1998). Additionally, data and sera from two other repositories related to CLD
were accessed to provide control groups. A total of 1863 adult ALF patients were enrolled from
23 tertiary care centers within the US between Jan. 1998 and Oct. 2010. Inclusion criteria defin-
ing ALF were the presence of coagulopathy (PT> 15 seconds or INR1.5 IU) and any grade
of hepatic encephalopathy (HE) that had occurred within 26 weeks of the first onset of symp-
toms. Enrolled patients may not have any CLD or cirrhosis, with the exception of certain
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patients with chronic hepatitis B or Wilson’s disease [15]. Written informed consent was
obtained for each subject from the next of kin because of altered mental status due to HE. All
centers were in compliance with their local institutional review board requirements. After
informed consent was obtained, serum samples and clinical data were collected daily for up to
7 consecutive days. Sample collection ended when one of the following events occurred: the
subject was discharged, transplanted, died, or completed the 7th study day. Serum samples
were stored frozen at -70° until testing.
The Chronic Liver Disease (CLDD; PI–William M. Lee, MD) and the Nucleic Acid, Serum,
and Tissue Repository for the Study of Liver Diseases Database and sample repositories
(NSTLD; PI–Marlyn Mayo, MD) are principal investigator-initiated studies at UT Southwest-
ern Medical Center (UTSW) in Dallas, TX. After written informed consent was obtained, sera
were obtained and frozen at -70° until testing.
This retrospective analysis received Institutional Review Board (IRB) approval from the
University of Texas Southwestern Medical Center (IRB#STU092010-126) and Virginia Com-
monwealth University (IRB#HM13517).
All study subjects were categorized into infection groups using modified definitions from
the 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference defini-
tions of systemic inflammatory response syndrome (SIRS), severe sepsis, and septic shock [9,
10, 16] based upon available data from the USALFSG database. Subjects with SIRS had to have
two or more of the following signs or symptoms: body temperature>38°C or<36°C, heart
rate>90 bpm, respiration rate>20 breaths/min, PCO2 level<32 mm Hg, WBC>12,000 or
<4,000, or bands (immature granulocytic white blood cells)>10%. Severe sepsis was defined as
organ failure in the presence of sepsis (SIRS plus a documented infection defined as a positive
culture (blood, trachea, wound, catheter or urine) up to 2 days prior to the blood sample). Sep-
tic shock was defined as the presence of severe persistent hypotension (mean arterial pressure
<60 mmHg) despite adequate volume resuscitation and pressor therapy in the presence of sep-
sis [16]. Non-infected/non-SIRS (non-SIRS) samples were selected from patients who met no
more than one of the SIRS criteria.
For the 1,863 patients enrolled in the ALF study, 12,492 days of demographic and bio-data
were sorted into 1 of the 4 groups: non-SIRS (n = 628), SIRS (n = 1407), severe sepsis
(n = 387), and septic shock (n = 31). Because the USALFSG is an observational study not spe-
cifically designed to study SIRS or infections, some data parameters noted in the 4 different
SIRS categories were either not captured by the ALF CRF or were not routinely collected on all
patient days (examples: cell differential, urine output, tachypnea, and cardiac index). Thus,
each patient day was categorized into a SIRS category based upon available data (i.e., if a lab
value was missing, it was considered to be negative for that parameter and, if present, consid-
ered positive if the parameter met positive criteria). Samples for the non-SIRS category were
only selected from days that had all available data and were negative for each parameter. Once
sorted into the 4 SIRS categories, 115 subjects were randomly selected, based upon sample
availability and maintaining a balance between the etiologies of their acute liver failure (acet-
aminophen toxicity, viral hepatitis or other etiologies). Currently, 46% of all ALF cases (in both
the USALFSG and the US) result from APAP toxicity, either suicidal overdoses or uninten-
tional excessive dosing [15]. To ensure a balanced distribution of etiologies, an equal number
of samples were requested for each etiology.
In addition, 10 subjects from each of the CLDD and NSTLD repositories were randomly
selected as negative controls. These subjects were ambulatory patients with CLD who had pro-
vided a screening blood sample during a routine clinic visit without symptoms. Limited bio-
data were available for this group. These subjects were considered to be non-SIRS and had no
clinical or laboratory evidence of bacterial infection.
Procalcitonin and Acute Liver Failure
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Immunoassay testing
The ADVIA Centaur BRAHMS PCT assay [17] is a sandwich immunoassay utilizing a mono-
clonal mouse antibody to fluorescein covalently linked to paramagnetic particles, a monoclonal
mouse antibody to procalcitonin that is labeled with acridinium ester and a second monoclonal
mouse antibody to procalcitonin labeled with fluorescein.
All testing was performed at Siemens Healthcare Diagnostics in Tarrytown, NY on a single
ADVIA Centaur. Siemens Healthcare Diagnostics, Tarrytown, NY, provided all reagents
required for testing.
Statistical Analyses
Descriptive statistics (median and range) are provided for all analyzed samples by group. A
Kruskal-Wallis test with post hoc testing (Dunn Method) was used to determine the utility of
PCT to detect infection, to examine possible measurement differences in PCT between patients
with CLD and ALF, and to determine the existence of a dose affect between PCT values and
severity of infection in ALF patients [18]. A Chi-square test was used as an alternative method
for analyzing patient groups and infection status. PCT values were categorized into infection
and non-infection groups using ROC analyses [19]. A 2-way analysis of variance was per-
formed to examine the difference in PCT by type of culture (blood vs. all other culture types),
severity categories (severe sepsis and septic shock), and the interaction of these two factors.
The median PCT values for the CLD, non-SIRS, and SIRS groups were compared to the ref-
erence range of the PCT assay. An expected reference value of<0.1 ng/mL had been previously
calculated from PCT values from a population of 456 normal subjects. The 95% confidence
interval for the mean concentration was 0.023 to 0.028 ng/mL [17]. SPSS version 20.0 (SPSS,
Chicago, IL) and SAS version 9.2 (Cary, NC) were used for statistical analyses.
Results
Study group characteristics based upon disease severity
Available demographic and laboratory data for the 115 study subjects and control groups are
shown in Tables 1 and 2. No discernible differences were apparent between the groups studied,
except that the CLD group was somewhat older and the overall ALF group contained more
women. Laboratory and certain clinical values differed significantly across the various study
groups generally reflecting severity of illness: WBC, platelets, INR, AST, ALT, creatinine, lac-
tate, pO2, O2 saturation, pCO2, pulse, respiration, and MAP.
Within the group of 115 ALF patients examined, all 56 with severe sepsis or septic shock
had demonstrated positive bacterial cultures (Table 1), and the CLD, non-SIRS, and SIRS
groups had no reported positive cultures on or prior to the study day. Blood stream infections
(with or without other positive cultures) were present in 23 of the 56, with the majority of the
remaining infections being tracheal, urinary tract or multiple without blood stream infection
(n = 16, 8 and 4 respectively).
Fig 1 and Table 2 present the median results for the PCT assay across all categories.
There was a significant difference between the CLD, non-SIRS and SIRS groups with a Chi-
square = 43.68 (df = 2, p-value<0.001) as well as between the CLD group and either the non-
SIRS or the SIRS groups (both p-values<0.001). However, there was no significant difference
between the non-SIRS and SIRS groups (p-value>0.05). When PCT results for CLD, non-
SIRS, and SIRS groups combined were compared to the documented reference value of the
PCT assay (<0.1 ng/mL—(17)), the median PCT value (0.97 ng/mL) was significantly higher
than the reference value (p<0.001). Results for the CLD group (median = 0.104 ng/mL)
Procalcitonin and Acute Liver Failure
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considered separately did not differ from the published reference range (p = 0.985), while
results from each of the other two groups (non-SIRS–median = 1.57 ng/mL and SIRS–
median = 2.29 ng/mL) were significantly higher than the reference and the CLD median value
(p<0.001 for both).
Table 1. Demographic Data for Patients Based Upon Severity of Illness Classifications.
Mean (± SD) or CLD non-SIRS SIRS Severe Sepsis Septic Shock
Number (%) n = 20 n = 30 n = 29 n = 40 n = 16 p-value
Age (years) 51 (29–71) 49 (19–86) 37 (18–66) 41 (17–73) 41 (19–71) 0.044
Gender
Female 10 (50) 15 (50) 21 (72.4) 33 (82.5) 12 (75) 0.019
Ethnicity*
Hispanic 5 (16.7) 5 (17.2) 5 (12.5) 1 (6.7)
Race** 0.672
White 14 (77.8) 21 (66.7) 23 (79.3) 33 (82.5) 14 (87.5)
African American 1 (5.6) 5 (16.7) 5 (17.2) 4 (10.0) 1 (6.2)
Asian 2 (11.1) 2 (6.7) 1 (3.4) 2 (5.0) 1 (6.2)
Hawaiian 1 (3)
Other 1 (5.6) 1 (3) 1 (2.5)
Diagnosis
APAP 10 (33.3) 10 (34.5) 16 (40.0) 5 (31.2)
Viral Hepatitis 10 (50) 10 (33.3) 10 (34.5) 7 (17.5) 1 (6.2)
Other 10 (50) 10 (33.3) 9 (31.0) 17 (42.5) 10 (62.5)
Outcome (TFS)
APAP 6 (20) 5 (17.2) 12 (30.0) 1 (6.2)
Viral Hepatitis 4 (13.3) 2 (6.9) 2 (7.4)
Other 1 (3.3) 4 (13.8) 5 (12.5) 1 (6.2)
Coma Grade
Not Reported / 0 20 (100) 4 (13.8) 3 (7.5)
1 11 (36.7) 1 (3.4) 4 (10.0)
2 11 (36.7) 8 (27.6) 1 (2.5)
3 4 (13.3) 5 (17.2) 11 (27.5) 1 (6.2)
4 4 (13.3) 11 (37.9) 21 (52.5) 15 (93.8)
Culture Types
Blood 6 5
Tracheal 12 4
Urine 5 3
Wound 3 1
Catheter 1
Multiple w Blood 10 2
Multiple w/o Blood 3 1
Antibiotics Used 19 (63.3) 23 (79.3) 33 (82.5) 13 (81.2) 0.294
Prophylaxis 15 (50) 17 (58.6) 19 (47.5) 10 (62.5) 0.673
Therapy 7 (23) 12 (41.4) 22 (55.0) 7 (43.8) 0.069
Age of Sample (years) 9 (1–15) 7 (2–13) 7 (2–13) 6 (2–13) 6.5 (2–11) 0.872
After Hospital Admission (days) 2 (0–11) 3 (0–51) 2 (0–22) 3 (0–16) 0.557
*Ethnicity: O were reported in the CLD group; 15 of 16 were reported in the Septic Shock group
**Race: 18 of 20 reported in the CLD group / p-value reported for white vs. all other races.
doi:10.1371/journal.pone.0138566.t001
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When PCT concentrations were compared across all categories, there was a significant differ-
ence between the CLD group and the four ALF categories (Chi-square = 53.98, p-value<0.001).
Post hoc pairwise testing indicated that the median PCT of the CLD group was significantly dif-
ferent from each of the ALF categories (p<0.001). However, there were no significant differences
observed (p = 0.169) between the four ALF categories themselves (non-SIRS, SIRS, severe sepsis
and septic shock). When we compared the PCT values between ALF subjects without a docu-
mented infection (non-SIRS and SIRS) to those with a documented infection (severe sepsis and
septic shock), there was no difference between the 2 groups (p = 0.082).
Subjects in severe sepsis and septic shock categories were examined based upon types of cul-
tures: blood cultures vs. all other culture types. There were no significant differences observed
for any of the 3 interactions: type of culture (p = 0.224), severity categories (p = 0.309), or the
interaction between these two factors (p = 0.241). There was also no difference observed
between the median PCT levels for subjects with positive blood cultures and those with positive
cultures from other sources.
Study group characteristics based upon PCT cut-off value
In previous studies, values of PCT above 2.0 ng/mL were considered to be associated with bac-
terial infection. While our non-SIRS and SIRS categories lacked evidence of infection, both
demonstrated median PCT values near or slightly above the 2.0 ng/mL cut-off, 1.57 and 2.29
respectively. Given the uncertainty concerning what a reasonable cut-off value for infection
should be for this population, we used a receiver operator characteristic (ROC) analysis, in
Table 2. Biodata and Laboratory values for Patients Based Upon Severity of Illness Classifications.
CLD non-SIRS SIRS Severe Sepsis Septic Shock
Median n = 20 n = 30 n = 29 n = 40 n = 16 p-value
Pulse [bpm] 80 96 108 112 <0.001
Respiration [breaths/min] 18 23 22 22 0.005
MAP [mmHg] 90.0 81.5 89.5 57.5 0.472*
Min Temp [°C] 36.6 35.9 36.5 36.0 0.200
Max Temp [°C] 36.8 36.7 37.4 34.3 0.101
Laboratory values
PCT [ng/mL] 0.104 1.57 2.29 2.51 5.89 <0.001
AST [IU/L] 787 360 292 3069 <0.001
ALT [IU/L] 1894 775 750 1520 0.030
WBC [x 103 /uL] 8.0 14.0 14.0 17.00 <0.001
Platelets[x 103 /uL] 143 88 115 61 0.002
Prothrombin time [secs] 27.5 25.0 21.0 25.0 0.124
INR [ratio] 3.0 2.0 2.0 3.0 0.030
Bilirubin [mg/dL] 15.0 10.0 10.0 12.5 0.902
Glucose [mg/dL] 122 103 110 145 0.997
Creatinine [mg/dL] 1.00 2.00 1.00 3.00 0.003
Lactate [mg/dL] 3.00 6.00 8.00 14.00 0.024
pO2 [mmHg] 117 86 107 93 0.025
pCO2 [mmHg] 34 27 27 25 <0.001
O2_saturation [%] 98 96 98 95 0.001
FiO2 [%] 28 40 40 50 0.056
pO2/FiO2 [ratio] 334 306.7 306.7 172.5 0.195
*Septic Shock was not included as MAP is deﬁned by the category.
doi:10.1371/journal.pone.0138566.t002
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which the optimal area under the curve (AUC) was equal to 0.697 (95% CI: 0.609–0.784), with
a cut-off value of 1.62 ng/mL, somewhat below the 2.0 ng/mL level (Fig 2). The cut-off value
determined from this set of data was made using a combination of criteria: 1) the point on the
curve that was at the greatest distance (0.186) from the 0.5 reference line at a 45° angle to the
line, 2) accuracy, 3) sensitivity (0.643), 4) specificity (0.620), and 5) likelihood ratio (1.693). We
used this 1.62 ng/mL cut-off for subsequent analyses.
When additional biochemical data ALF between subjects with a PCT that was<1.62 ng/mL
and from those with a PCT that was1.62 ng/mL were compared, platelet, creatinine, AST,
ALT, and bilirubin showed significant differences between the theoretically ‘infected’ (above
the cut-off) and ‘non-infected’ (below the cut-off) groups (Table 3). Of interest, 85.4% of all
APAP subjects had values above the 1.62 ng/mL level while only 21 of 41 (51.2%) of the APAP
subjects had a documented bacterial infection. In the non-APAP subjects, 43.2% had values
above 1.62 ng/mL with documented bacterial infection in 35 of 74 (47.3%) of the subjects.
When PCT results were examined based solely upon etiology, median values for subjects
with APAP toxicity were typically much higher, between 3.0 and 6.6 times higher than the
results observed for the same severity category for subjects with non-APAP etiologies (Fig 3).
Fig 1. Median PCT Values by Category. This graph represents the median PCT values for the five patient
severity groups. The lower dashed horizontal line represents the 0.1 ng/mL PCT cut-off value indicative of no
infection. The upper dotted horizontal line represents the 2.0 ng/mL PCT cut-off value indicative of severe
sepsis.
doi:10.1371/journal.pone.0138566.g001
Procalcitonin and Acute Liver Failure
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Discussion
In this study of ALF patients selected for increasing severity of SIRS features and for the pres-
ence of bacterial infection, PCT measurement disclosed markedly elevated values but did not
provide any direct correlation to presence or absence of infection. Determining the presence
with certainty of systemic infection in those with advance SIRS features is problematic in a ret-
rospective study; we assumed that the presence of advanced SIRS features plus positive cultures
was the best surrogate for systemic infection and this may not be the case in every instance.
However, virtually all ALF subjects displayed PCT values well above both the 0.1 ng/mL refer-
ence value and the median value observed in the CLD controls, regardless of any evidence for
infection, particularly high values being observed in a large group that demonstrated no evi-
dence for infection. The differences in PCT levels between severity categories among ALF
patients were not significant due apparently to elevated levels in the absence of infection. Thus,
Fig 2. Receiver Operator Curve for the Detection of Infection in ALF and ALI patients Using PCT. The ROC analysis resulted in an AUC of 0.697 with a
sensitivity of 64.3% and a specificity of 62.0% for the use of PCT in the detection of infection this population of ALF patients.
doi:10.1371/journal.pone.0138566.g002
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both the non-SIRS and SIRS categories that would be expected to show low or normal PCT lev-
els demonstrated PCT levels approximating those that have been observed previously in other
studies during active bacterial infection in a non-ALF setting.
Using a cut-off value determined by the ROC analysis, the presumed uninfected categories
(non-SIRS and SIRS) included 31 patients with elevated PCTs (1.62 ng/mL). Of these sub-
jects, 13 demonstrated signs of infection (bacterial or fungal, n = 5 each) 1 or more days after
the PCT sample was collected or other evidence of infection upon closer examination of the
each subject’s case report form (CRF), including pancreatitis, tooth abscess or ventilator
acquired pneumonia with infiltrate on x-ray. Subjects with fungal infections were classified as
culture negative since values of PCT in yeast and fungal infections have been observed to be
lower than those seen with most bacterial infections [20].
The median PCT values in the severe sepsis and septic shock categories (3.46 ng/mL and
589 ng/mL, respectively), were both well above the 1.62 ng/mL calculated cut-off and 2.0 ng/
mL literature cut-off for severe sepsis [10], but these were not significantly different from the
Table 3. Demographic and Biodata Results Based Upon the Calculated Infection Cut-off Value of 1.62 ng/mL.
Median or Number (%) PCTs < 1.62 ng/mL n = 48 PCT  1.62 ng/mL n = 67 p-value
ALF Etiology
APAP 6 (12.5) 35 (52.2)
Viral hepatitis 17 (34.7) 11 (16.4)
Other 25 (51.0) 21 (31.3)
Outcome (TFS)
APAP 3 (6.2) 21 (31.3)
Viral Hepatitis 5 (10.4) 3 (4.4)
Other 5 (10.4) 6 (9.0)
Procalcitonin [ng/mL] 0.6904 5.325 <0.001
WBC [x 103 /uL] 13.0 13.0 0.740
Platelets [x 103 /uL] 135 92 0.019
INR [ratio] 2.0 2.0 0.786
Glucose [mg/dL] 115.5 120.0 0.787
Creatinine [mg/dL] 1.0 2.0 <0.001
AST [IU/L] 337 913 0.06
ALT [IU/L] 684 1759 0.07
Lactate [mg/dL] 3.5 6.0 0.230
Bilirubin [mg/dL] 19.0 7.0 <0.001
pO2 [mmHg] 92.5 103.0 0.707
pCO2 [mmHg] 29.0 27.0 0.108
Pulse [bpm] 84 68 0.084
Respiration [breaths/min] 17 13 0.094
Min Temp [°C] 36.0 37.0 0.298
Max Temp [°C] 37.0 37.0 0.298
Coma Grade
0 / Not reported 3 4
1 7 9
2 12 8
3 9 12
4 18 33
Samples were resorted based upon the cut-off value of 1.62 ng/mL and demographic and biodata were re-examined.
doi:10.1371/journal.pone.0138566.t003
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median PCT values in non-SIRS and SIRS patients without documented infection. Of interest,
17 of 40 severe sepsis subjects and 3 of 16 septic shock subjects had PCT values below the 1.62
ng/mL cut-off. Prophylactic antibiotics might provide a partial explanation for lower PCT val-
ues during a documented infection but, overall, the decreased results remain unexplained. Full
bacterial culture reports were not collected as part of the USALFSG study nor did the study
case report forms capture information related to quantity of bacterial growth or antibiotic sen-
sitivities that might have helped determine some the differences among the various severity
groups.
Upon examining results according to etiology, subjects with APAP toxicity demonstrated
much higher PCT levels than any other etiologies. It seems likely that the elevated PCT values
in these subjects are not indicative of infection. Rather, APAP toxicity unleashes an inflamma-
tory response, with macrophage activation, release of cytokines and pro-inflammatory regula-
tors including TNF-alpha that may secondarily contribute to liver injury and the appearance of
a septic milieu [21, 22]. While the exact origin and pathogenic pathway of PCT stimulation is
still unknown, it has been suggested that PCT is produced by neuroendocrine cells in the liver
while other data suggest that it is released by macrophages [23]. It is also possible that increases
in PCT may be initiated by TNF-alpha and IL-1b [24, 25]. It appears that in the acute liver fail-
ure setting PCT is increased due in large part to the massive inflammatory response to liver
Fig 3. Median APAP vs All Other Etiologies PCT values by Category. This graph represents the median PCT values for the four ALF patient severity
groups sorted by etiologies: APAP and All Others etiologies (combined viral and other) with the lower dashed line indicative of no infection (0.1 ng/mL) and
the upper dotted line indicative of severe sepsis (2.0 ng/mL).
doi:10.1371/journal.pone.0138566.g003
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injury, particularly in the case of acetaminophen toxicity. While we did see higher PCT levels
in patients with bacterial infections, if PCT is to be useful in this population, a better under-
standing of the mechanism of PCT production will need to be ascertained.
Prior studies examining PCT values in the acute liver failure setting have been limited. Stud-
ies in patients with chronic liver disease (cirrhosis) [26–29], liver metastasis of non-liver pri-
mary solid tumors [23], and other acute and chronic liver diseases have been performed [30].
While baseline PCT values increased as the severity of the underlying liver disease increased,
an elevated PCT was indicative of bacterial infection. A previous study of PCT use in ALF
patients due to APAP toxicity also showed increased PCT values in subjects without evidence
of bacterial infection [14], similar to our findings.
We considered whether the use of older retrospective samples from the ALFSG repository
might affect results, since long-term sample storage may decrease observed PCT levels.
Schuetz, et al. studied two sets of samples that were stored at -80°C for 4.8 to 5.5 years and 3.3
to 4.6 years [31]. The PCTs for each set decreased by 11.4% and 13.5% respectively. Samples
used in this study had been stored an average of approximately 6.75 years at -80°C. While it is
assumed that the length of time in storage might have decreased the PCT values obtained, the
exact amount of decrease is unknown and an estimate of the extent of the effect cannot be cal-
culated. However, since each sample group had similarly aged samples, this would appear to
negate a specific effect on the overall study results (Table 1).
Conclusion
Procalcitonin detects bacterial infection and sepsis in the general population, but appears to be
a more general marker of moderate to severe inflammation. As such, it has limited value as a
single marker to discriminate between the presence or absence of bacterial infection in the set-
ting of acute liver failure but may be of value in combination with other markers. PCT eleva-
tions appeared to be roughly proportional to the degree of hepatic necrosis. A prospective
study with a larger sample size employing prospective determination of infection and standard-
ized antibiotic usage might provide additional information regarding the relationship between
PCT and severe liver injury, particularly APAP toxicity.
Supporting Information
S1 Data. Study Clinical and Laboratory Data.
(XLSX)
Acknowledgments
Members and institutions participating in the Acute Liver Failure Study Group 1998–2011 are
as follow: William M. Lee, M.D. (Principal Investigator), The University of Texas Southwestern
Medical Center, Dallas, TX; Anne M. Larson, M.D., Iris Liou, M.D., University of Washington,
Seattle, WA; Timothy Davern, M.D., University of California, San Francisco, CA (current
address: California Pacific Medical Center, San Francisco, CA), Oren Fix, M.D., University of
California, San Francisco; Michael Schilsky, M.D., Mount Sinai School of Medicine, New York,
NY (current address: Yale University, New Haven, CT); Timothy McCashland, M.D., Univer-
sity of Nebraska, Omaha, NE; J. Eileen Hay, M.B.B.S., Mayo Clinic, Rochester, MN; Natalie
Murray, M.D., Baylor University Medical Center, Dallas, TX; A. Obaid S. Shaikh, M.D., Uni-
versity of Pittsburgh, Pittsburgh, PA; Andres Blei, M.D., Northwestern University, Chicago, IL
(deceased), Daniel Ganger, M.D., Northwestern University, Chicago, IL; Atif Zaman, M.D.,
University of Oregon, Portland, OR; Steven H.B. Han, M.D., University of California, Los
Procalcitonin and Acute Liver Failure
PLOS ONE | DOI:10.1371/journal.pone.0138566 September 22, 2015 11 / 13
Angeles, CA; Robert Fontana, M.D., University of Michigan, Ann Arbor, MI; Brendan
McGuire, M.D., University of Alabama, Birmingham, AL; Raymond T. Chung, M.D., Massa-
chusetts General Hospital, Boston, MA; Alastair Smith, M.B., Ch.B., Duke University Medical
Center, Durham, NC; Robert Brown, M.D., Cornell/Columbia University, New York, NY; Jef-
frey Crippin, M.D., Washington University, St Louis, MO; Edwyn Harrison, Mayo Clinic,
Scottsdale, AZ; Adrian Reuben, M.B.B.S., Medical University of South Carolina, Charleston,
SC; Santiago Munoz, M.D., Albert Einstein Medical Center, Philadelphia, PA; Rajender Reddy,
M.D., University of Pennsylvania, Philadelphia, PA; R. Todd Stravitz, M.D., Virginia Com-
monwealth University, Richmond, VA; Lorenzo Rossaro, M.D., University of California Davis,
Sacramento, CA; Raj Satyanarayana, M.D., Mayo Clinic, Jacksonville, FL; and Tarek Hassa-
nein, M.D., University of California, San Diego, CA. The University of Texas Southwestern
Administrative Group included Grace Samuel, Ezmina Lalani, Carla Pezzia, and Corron Sand-
ers, Ph.D., Nahid Attar, Jody A. Balko, Ph.D., the University of Texas Southwestern Statistics
and Data Management Group included Joan Reisch, PhD, Linda Hynan, PhD, Janet P. Smith,
Joe W. Webster, and Mechelle Murry, and the Medical University of South Carolina Data
Coordination Unit included Valerie Durkalski, Ph.D., Wenle Zhao, Ph.D., Catherine Dillon,
Holly Battenhouse and Tomoko Goddard.
Author Contributions
Conceived and designed the experiments: JAR LSHWJKWML. Performed the experiments:
JAR. Analyzed the data: JAR LSHWML. Contributed reagents/materials/analysis tools: JAR
LSH. Wrote the paper: JAR LSH. Sample and data selection and procurement: NA CS.
References
1. Rolando N, Wade J, Davalos M, Wendon J, Philpott-Howard J, Williams R. The systemic inflammatory
response syndrome in acute liver failure. Hepatology, 2000; 32(4): 734–739. PMID: 11003617
2. Rolando N, Wade J, Davalos M, Wendon J, Philpott-Howard J, Williams R. Timing and aetiology of bac-
terial infections in a liver intensive care unit. J Hosp Infect, 2003; 53(2): 144–146. PMID: 12586576
3. Stravitz RT. Critical management decisions in patients with acute liver failure. Chest, 2008; 134: 1092–
1102. doi: 10.1378/chest.08-1071 PMID: 18988787
4. Vaquero J, Polson J, Chung C, Helenowski I, Schiodt FV, Reisch J, et al. Infection and the progression
of hepatic encephalopathy in acute liver failure. Gastroenterology, 2003; 125(3): 755–764. PMID:
12949721
5. Becker KL, Nylen ES, White JC, Muller B, Snider RH, Jr. Procalcitonin and the calcitonin gene family of
peptides in inflammation, infection, and sepsis: A journey from calcitonin back to its precursors. J Clin
Endocrinol Metab, 2004; 89(4): 1512–1525. PMID: 15070906
6. Bracq S, Machairas M, Clement B, Pidoux E, Andreoletti M, Mokhtar MS, et al. Calcitonin gene expres-
sion in normal human liver. FEBS Letters, 1993; 331(1,2): 15–18.
7. Carrol ED, Thomson APJ, Hart CA. Procalcitonin as a marker of sepsis. Int J Antimicrob Agents, 2002;
20: 1–9. PMID: 12127705
8. Muller B, Becker KL. (2001). Procalcitonin: How a hormone became a marker and mediator of sepsis.
Swiss Medi Wkly, 2001; 131(41–42): 595–602.
9. Brunkhorst FM, Wegscheider K, Forycki ZF, Brunkhorst R. Procalcitonin for early diagnosis and differ-
entiation of SIRS, sepsis, severe sepsis, and septic shock. Intensive Care Med, 2000; 26: S148–S152.
doi: 10.1007/BF02900728 PMID: 18470710
10. Harbarth S, Holeckova K, Froidevaux C, Pittet D, Ricou B, Grau GE, et al. Diagnostic value of procalci-
tonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. American
Journal of Respiratory Critical Care Medicine, 2001; 164: 396–402. PMID: 11500339
11. Brunkhorst FM, Eberhard OK, Brunkhorst R. Discrimination of infectious and noninfectious causes of
early acute respiratory distress syndrome by procalcitonin. Crit Care Med, 1999; 27(10): 2172–2176.
PMID: 10548201
Procalcitonin and Acute Liver Failure
PLOS ONE | DOI:10.1371/journal.pone.0138566 September 22, 2015 12 / 13
12. Luyt C, Guerin V, Combes A, Trouillet J, Ayed SB, Bernard M, et al. Procalcitonin kinetics as a prognos-
tic marker of ventilator-associated pneumonia. Am J Respir Crit Care Med, 2005; 171: 48–53. PMID:
15447947
13. Meisner M, Tschaikowsky K, Hutzler A, Schick C, Schuttler J. Postoperative plasma concentrations of
procalcitonin after different types of surgery. Intensive Care Med, 1998; 24: 680–684. PMID: 9722037
14. Jackson N, Batouche S, Sherwood R, Wendon J. Serial plasma procalcitonin levels in patients requir-
ing admission to liver ITU with paracetamol induced acute liver failure. Abstract Brit J Anaesth, 2000;
84 (5): 92P.
15. LeeWM, Squires RH Jr, Nyberg SL, Doo E, Hoofnagle JH. Acute liver failure: Summary of a workshop.
Hepatology, 2008; 47: 1401–1415. doi: 10.1002/hep.22177 PMID: 18318440
16. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/
SIS international sepsis definitions conference. Crit Care Med, 2003; 31(4): 1250–1256. PMID:
12682500
17. Siemens Healthcare Diagnostics, Ltd. Advia centaur and advia centaur XP systems—procalcitonin
(PCT). Frimley, Camberley, UK; 2010. Rev B.
18. Elliot AC, Hynan LS. A SAS
1
macro implementation of a multiple comparison post hoc test for a Krus-
kal-Wallis analysis. Comput Methods Programs Biomed, 2011; 102(1): 75–80. doi: 10.1016/j.cmpb.
2010.11.002 PMID: 21146248
19. Riffenburgh RH. Statistics in Medicine. Second Edition. New York, NY, Elsevier, 2006.
20. Nakamura A, Wada S, Takeda T, Nobori T. Efficacy of procalcitonin in the early diagnosis of bacterial
infections in a critical care unit. Shock, 2009; 31(6): 586–591. doi: 10.1097/SHK.0b013e31819716fa
PMID: 19060784
21. Dragomir A-C, Laskin JD, Laskin DL. Macrophage activation by factors released from acetaminophen-
injured hepatocytes: Potential role of HMGB-1. Toxicol Appl Pharmacol, 2011; 253: 170–177. doi: 10.
1016/j.taap.2011.04.003 PMID: 21513726
22. Jaeschke H, McGill MR, Ramachandran A. Oxidant stress, mitochondria, and cell death mechanisms
in drug-induced liver injury: Lessons learned from acetaminophen hepatotoxicity. Drug Metab Rev,
2012; 44(1): 88–106. doi: 10.3109/03602532.2011.602688 PMID: 22229890
23. Matzaraki V, Alexandraki KI, Venetsanou K, Piperi C, Myrianthefs P, Malamos N, et al. Evaluation of
serum procalcitonin and interleukin-6 levels as markers of liver metastasis. Clin Biochem, 2007; 40:
336–342. PMID: 17306245
24. Whang KT, Vath SD, Nylen ES, Muller B, Li Q, Tamarkin L, et al. Procalcitonin and proinflammatory
cytokine interactions in sepsis. Shock, 1999; 12(4): 268–273. PMID: 10509628
25. Domenech VS, Nylen ES, White JC, Snider RH Jr, Becker KL, Landmann R, et al. Calcitonin gene-
related peptide expression in sepsis: Postulation of microbial infection-specific response elements
within the calcitonin I gene promoter. J Investig Med, 2001; 49(6): 514–521. PMID: 11730087
26. Bota DP, Van Nuffelen M, Zakariah AN, Vincent JL. Serum levels of C-reactive protein and procalcito-
nin in critically ill patients with cirrhosis of the liver. J Lab Clin Med, 2005; 146(6): 347–351. PMID:
16310518
27. Connert S, Stremmel W, Eising C. Procalcitonin is a valid marker of infection in decompensated cirrho-
sis. Abstract Z Gastroenterol, 2003; 41(2): 165–170.
28. Spahr L, Morard I, Hadengue A, Vadas L, Pugin J. Procalcitonin is not an accurate marker of spontane-
ous bacterial peritonitis in patients with cirrhosis. Hepatogastroenterology, 2001; 48(38): 502–505.
PMID: 11379342
29. Viallon A, Zeni F, Pouzet V, Lambert C, Quenet S, Tardy B, et al. Serum and ascitic procalcitonin levels
in cirrhotic patients with spontaneous bacterial peritonitis: Diagnostic value and relationship to pro-
inflammatory cytokines. Intensive Care Med, 2000; 26: 1082–1086. PMID: 11030164
30. Elefsiniotis IS, Skounakis M, Vezali E, Pantazis KD, Petrocheilou A, Pirounaki M, et al. Clinical signifi-
cance of serum procalcitonin levels in patients with acute or chronic liver disease. Eur J Gastroenterol
Hepatol, 2006; 18(5): 525–530. PMID: 16607149
31. Schuetz P, Christ-Crain M, Huber AR, Muller B. Long-term stability of procalcitonin in frozen samples
and comparison of kryptor and VIDAS automated immunoassays. Clin Biochem, 2010; 43(3): 341–
344. doi: 10.1016/j.clinbiochem.2009.08.029 PMID: 19747473
Procalcitonin and Acute Liver Failure
PLOS ONE | DOI:10.1371/journal.pone.0138566 September 22, 2015 13 / 13
